Related Experiment Video
Updated: Jan 8, 2026
Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
Published on: June 26, 2013
Material-based neuroimaging and biomarker detection for central nervous system disorder
Liqun Yu1,2, Yanjing Zhu1,2,3,4, Xinxin Zheng1,2
1Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Tongji Hospital Affiliated to Tongji University, School of Medicine, School of Life Science and Technology, Tongji University, Shanghai, 200065, China.
Nanomaterials revolutionize central nervous system (CNS) disorder diagnostics by enhancing neuroimaging and biomarker detection. These advanced materials offer improved blood-brain barrier penetration for earlier and more precise diagnosis of neurological conditions.
Area of Science:
- Nanotechnology and Materials Science
- Neuroscience
- Medical Imaging
Background:
- Central nervous system (CNS) disorders are challenging to diagnose early due to non-specific symptoms, sensitive diagnostic limitations, and the blood-brain barrier (BBB).
- Conventional diagnostic methods often lack the sensitivity and specificity required for early detection of neurodegenerative diseases, brain tumors, and cerebrovascular conditions.
- The restrictive nature of the BBB poses a significant hurdle for delivering diagnostic agents and therapeutics to the brain.
Purpose of the Study:
- To review recent advances in nanomaterial-based platforms for neuroimaging and biomarker detection in CNS disorders.
- To summarize progress in various material-based imaging modalities and nanoparticle-enabled biosensors.
- To discuss the integration of these technologies with artificial intelligence for improved diagnostic strategies.
Main Methods:
- Review of material-based magnetic resonance imaging (MRI) and positron emission tomography (PET).
- Exploration of emerging imaging modalities: photoacoustic, near-infrared, and surface-enhanced Raman scattering (SERS) imaging.
- Discussion of nanoparticle-enabled biosensors for detecting key CNS biomarkers (Aβ, tau, α-synuclein, NFL, microRNAs) in biofluids.
Main Results:
- Nanomaterials enable high-resolution, targeted, and multimodal neuroimaging.
- Nanoparticle-based biosensors show promise for sensitive detection of CNS biomarkers in cerebrospinal fluid, blood, and other biofluids.
- Integration with AI enhances BBB penetration, targeting precision, and personalized diagnostics.
Conclusions:
- Material-enabled platforms are transforming precision diagnostics and therapeutic monitoring for CNS disorders.
- Further research requires rigorous safety profiling, standardized metrics, and multicenter trials for clinical translation.
- These advancements offer new possibilities for improving patient outcomes in neurology.
